CAS
SLXP

CTC Alternative Strategies’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

CTC Alternative Strategies’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,000
Closed -$247K – 255
2014
Q2 		$247K Buy
+2,000
New +$221K 0.21% 144

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CTC Alternative Strategies's SLXP Position: Q3 2014 in Review

CTC Alternative Strategies sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2014, closing a stake of 2,000 shares — an estimated $247K sold.

CTC Alternative Strategies first reported a position in SLXP in Q2 2014 and held it in 1 quarter. The position peaked at $247K in Q2 2014. 348 funds tracked by Wall St. Rank hold SLXP as of Q3 2014.

  • CTC Alternative Strategies reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2014 after selling out during the quarter.
  • CTC Alternative Strategies sold 2,000 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2014, an estimated $247K.
  • CTC Alternative Strategies first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2014 and held it in 1 quarter.
  • CTC Alternative Strategies's SALIX PHARMACEUTICALS LTD DEL position peaked at $247K in Q2 2014.
  • 348 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2014.

Based on CTC Alternative Strategies's 13F filing for Q3 2014, filed 14 Nov 2014.